Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
Evofem Biosciences (OTCQB: EVFM) is addressing concerns about the impact of GLP-1 receptor agonists on oral contraceptive effectiveness. These medications, used for obesity and type 2 diabetes treatment, can cause gastrointestinal side effects that may reduce oral contraceptive absorption. Evofem offers Phexxi, a hormone-free, on-demand contraceptive gel, as a non-oral alternative.
Phexxi maintains the vagina's acidic pH, creating an environment inhospitable to sperm. It's particularly suitable for women using GLP-1 medications who are concerned about potential drug interactions affecting their birth control efficacy. Evofem's CEO, Saundra Pelletier, emphasizes the importance of understanding these interactions and providing alternative contraceptive options for women managing chronic conditions like obesity and diabetes.
Evofem Biosciences (OTCQB: EVFM) sta affrontando le preoccupazioni riguardo all'impatto degli agonisti del recettore GLP-1 sull'efficacia dei contraccettivi orali. Questi farmaci, utilizzati per il trattamento dell'obesità e del diabete di tipo 2, possono causare effetti collaterali gastrointestinali che potrebbero ridurre l'assorbimento dei contraccettivi orali. Evofem offre Phexxi, un gel contraccettivo privo di ormoni, disponibile su richiesta, come alternativa non orale.
Phexxi mantiene il pH acido della vagina, creando un ambiente poco favorevole agli spermatozoi. È particolarmente adatto per le donne che assumono farmaci GLP-1 e sono preoccupate per le possibili interazioni farmacologiche che potrebbero influenzare l'efficacia del loro contraccettivo. La CEO di Evofem, Saundra Pelletier, sottolinea l'importanza di comprendere queste interazioni e di fornire opzioni contraccettive alternative per le donne che gestiscono condizioni croniche come l'obesità e il diabete.
Evofem Biosciences (OTCQB: EVFM) está abordando las preocupaciones sobre el impacto de los agonistas del receptor GLP-1 en la efectividad de los anticonceptivos orales. Estos medicamentos, utilizados para el tratamiento de la obesidad y la diabetes tipo 2, pueden causar efectos secundarios gastrointestinales que pueden reducir la absorción de los anticonceptivos orales. Evofem ofrece Phexxi, un gel anticonceptivo sin hormonas, disponible bajo demanda, como una alternativa no oral.
Phexxi mantiene el pH ácido de la vagina, creando un ambiente hostil para los espermatozoides. Es particularmente adecuado para las mujeres que usan medicamentos GLP-1 y están preocupadas por las posibles interacciones medicamentosas que afectan la eficacia de su anticonceptivo. La CEO de Evofem, Saundra Pelletier, enfatiza la importancia de comprender estas interacciones y de proporcionar opciones anticonceptivas alternativas para las mujeres que manejan condiciones crónicas como la obesidad y la diabetes.
Evofem Biosciences (OTCQB: EVFM)는 GLP-1 수용체 작용제가 경구 피임약의 효과에 미치는 영향에 대한 우려를 해결하고 있습니다. 이러한 약물은 비만 및 제2형 당뇨병 치료에 사용되며, 위장관 부작용을 일으켜 경구 피임약의 흡수를 저하할 수 있습니다. Evofem은 호르몬이 없는 수요 기반 피임 젤인 Phexxi를 비경구 대체제로 제공합니다.
Phexxi는 질의 산성 pH를 유지하여 정자에게 적합하지 않은 환경을 조성합니다. GLP-1 약물을 사용하는 여성에게 특히 적합하며, 출산 통제 효능에 영향을 미칠 수 있는 약물 상호작용에 대한 우려가 있습니다. Evofem의 CEO인 순간다 펠레티에는 이러한 상호작용을 이해하고 비만 및 당뇨병과 같은 만성 질환을 관리하는 여성들에게 대체 피임 옵션을 제공하는 것이 중요하다고 강조합니다.
Evofem Biosciences (OTCQB: EVFM) aborde les préoccupations concernant l'impact des agonistes du récepteur GLP-1 sur l'efficacité des contraceptifs oraux. Ces médicaments, utilisés pour traiter l'obésité et le diabète de type 2, peuvent provoquer des effets secondaires gastro-intestinaux qui peuvent réduire l'absorption des contraceptifs oraux. Evofem propose Phexxi, un gel contraceptif sans hormones et à la demande, comme alternative non orale.
Phexxi maintient le pH acide du vagin, créant un environnement peu propice aux spermatozoïdes. Il est particulièrement adapté aux femmes utilisant des médicaments GLP-1 qui craignent les interactions médicamenteuses pouvant affecter l'efficacité de leur contraception. La PDG d'Evofem, Saundra Pelletier, souligne l'importance de comprendre ces interactions et de fournir des options contraceptives alternatives pour les femmes gérant des maladies chroniques telles que l'obésité et le diabète.
Evofem Biosciences (OTCQB: EVFM) geht den Bedenken hinsichtlich der Auswirkungen von GLP-1-Rezeptor-Agonisten auf die Wirksamkeit von oralen Kontrazeptiva nach. Diese Medikamente, die zur Behandlung von Fettleibigkeit und Typ-2-Diabetes eingesetzt werden, können gastrointestinale Nebenwirkungen hervorrufen, die die Absorption oraler Kontrazeptiva verringern können. Evofem bietet Phexxi, ein hormonfreies, bedarfsorientiertes Kontrazeptivgel, als nicht-orale Alternative an.
Phexxi erhält den sauren pH-Wert der Vagina und schafft ein für Spermien ungünstiges Umfeld. Es ist besonders geeignet für Frauen, die GLP-1-Medikamente verwenden und sich um mögliche Wechselwirkungen mit Arzneimitteln sorgen, die die Wirksamkeit der Geburtenkontrolle beeinträchtigen können. Die CEO von Evofem, Saundra Pelletier, betont die Bedeutung des Verständnisses dieser Wechselwirkungen und der Bereitstellung alternativer Verhütungsoptionen für Frauen, die chronische Erkrankungen wie Fettleibigkeit und Diabetes managen.
- Phexxi offers a non-oral contraceptive solution for women using GLP-1 medications
- Phexxi is hormone-free and on-demand, providing flexibility for users
- Addresses a growing market need as GLP-1 medication usage increases
- Potential market to women using GLP-1 medications or those concerned about oral contraceptive effectiveness
Insights
The rising use of GLP-1 medications for obesity and diabetes presents a significant challenge for women relying on oral contraceptives. These drugs' gastrointestinal side effects can potentially reduce the absorption and effectiveness of birth control pills, increasing the risk of unintended pregnancies. This situation creates a growing market opportunity for non-oral contraceptives like Phexxi. As a hormone-free, on-demand gel, Phexxi offers a unique value proposition by maintaining vaginal pH to inhibit sperm, avoiding the absorption issues associated with oral methods. This positions Evofem Biosciences to potentially capture a niche market of women seeking alternative contraception while on GLP-1 therapies. However, it's important to note that Phexxi's effectiveness (
Evofem's strategy to target users of GLP-1 medications is a smart move in a rapidly expanding market. The global GLP-1 receptor agonist market is projected to reach
Evofem's focus on the GLP-1 user segment could potentially boost Phexxi sales, but investors should approach with caution. The company's financial health is concerning, with a history of significant losses and cash burn. In Q2 2023, Evofem reported net product sales of only
GLP-1 receptor agonists, including well-known medications such as semaglutide and tirzepatide, are celebrated for their ability to aid in weight loss and improve blood sugar levels. However, these medications are also associated with gastrointestinal side effects, including nausea, vomiting, and delayed gastric emptying, which can interfere with the absorption of oral contraceptives. This reduced absorption can make oral birth control less effective, increasing the risk of unintended pregnancies.
Evofem Biosciences is proud to offer Phexxi® (lactic acid, citric acid and potassium bitartrate), a hormone-free, on-demand contraceptive gel that provides women with a reliable non-oral birth control option. Phexxi is uniquely suited for patients who are prescribed GLP-1 medications and are concerned about the potential for reduced effectiveness of oral contraceptives due to drug-drug interaction.
"The rise in GLP-1 usage brings important considerations for women's reproductive health," said Saundra Pelletier, CEO of Evofem Biosciences. "Understanding the impact of these medications on oral contraceptive absorption and effectiveness is critical. Phexxi offers a non-oral alternative that allows women to manage their contraception without worrying about compromised absorption."
Phexxi works by maintaining the vagina's slightly acidic pH, counteracting the influence of semen and sustaining an environment that is inhospitable to sperm. As a non-hormonal, on-demand contraceptive, Phexxi is used only when needed, making it a flexible and convenient option for women who are concerned about the potential interactions between their GLP-1 medication and oral contraceptives.
Evofem Biosciences is committed to supporting women's health by providing innovative solutions that address the unique challenges faced by women who are managing chronic conditions such as obesity and diabetes. By offering Phexxi as a non-oral contraceptive option, Evofem is empowering women to take control of their reproductive health without compromising the effectiveness of their GLP-1 treatment plans.
About Evofem Biosciences
Evofem Biosciences, Inc., is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.
In July 2024 Evofem broadened its commercial offering with the acquisition of SOLOSEC® (secnidazole) 2g oral granules, an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose.
In December 2023, Evofem entered into a Merger Agreement with Aditxt, Inc. (Nasdaq: ADTX) under which Aditxt intends to acquire Evofem. The parties amended and restated the Merger Agreement, as amended, in its entirety in July 2024 and are targeting to close in late 2024.
Follow us on:
LinkedIn: https://www.linkedin.com/company/evofem
Facebook: http://www.facebook.com/Evofem
X (f/k/a Twitter): https://x.com/Evofem
Phexxi® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.
Important Safety Information
- Rare cases (
0.36% ) of bladder and kidney infection have been reported. If you have a history of urinary tract problems that keep coming back, you should not use Phexxi®. - Contact your healthcare provider if you are experiencing genitourinary side effects such as vaginal burning, itching, discharge, genital discomfort (including in male partners), yeast infection, urinary tract infection or bacterial vaginosis.
- Phexxi does not protect against any sexually transmitted infections, including HIV.
- Avoid using Phexxi with a vaginal ring.
- Avoid Phexxi if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the ingredients in Phexxi. Stop using Phexxi if you develop an allergic reaction.
For more information about Phexxi, talk to your healthcare provider and see full Product Information.
Please report side effects by contacting Evofem Biosciences® toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements related to the Company's anticipated financial performance, expected timing to relaunch SOLOSEC, and the likelihood of success and anticipated timing to close the contemplated Aditxt transaction. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 27, 2024, Quarterly Report on Form 10-Q for the three months ended March 31, 2024 filed with the SEC on May 12, 2024, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.
Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
ir@evofem.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-addresses-the-impact-of-glp-1-medications-on-oral-contraceptive-absorption-and-introduces-phexxi-as-a-non-oral-solution-302225957.html
SOURCE Evofem Biosciences, Inc.
FAQ
How does Phexxi work as a contraceptive?
Why is Evofem Biosciences (EVFM) focusing on GLP-1 medication users?
What are the advantages of Phexxi for women using GLP-1 medications?
When did Evofem Biosciences announce this focus on GLP-1 medication users?
